SYSTEMIC LUPUS ERYTHEMATOSUS
The updated 2019 diagnostic criteria for SLE require an ANA titer of 80 or more on HEp-2 cells, highlighting that SLE should almost never be diagnosed if the ANA titer is negative.
EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Mepolizumab, an IL-5 inhibitor, is FDA approved for the treatment of eosinophilic granulomatosis with polyangiitis, although it has not been studied specifically for severe life- or organ-threatening vasculitic disease manifestations (which generally require cyclophosphamide).
Interferon-free direct-acting antiviral agents are preferred because of the excellent long-term response in clinical trials.
In patients with active psoriatic arthritis, a TNF inhibitor biologic agent is recommended as first-line agent.
RHEUMATOLOGIC MANIFESTATIONS OF CANCER
The persistence of some autoimmune conditions as adverse events from cancer immunotherapy despite cessation of cancer treatment, namely inflammatory arthritis, may require longterm immunosuppression.